** Cogent Biosciences COGT.O looks to capitalize on its soaring stock price to raise capital via equity and convertible debt deals

** COGT shares on Mon closed up 119% at 7-year high $32.46 after its drug, bezuclastinib, in combination with Pfizer's PFE.N Sutent slowed stomach cancer progression in late-stage trial

** After the bell, co commences concurrent public offerings of $200 mln of convertible bonds (CBs) due 2031 and $200 mln of shares

** It intends to use net offering proceeds from the offerings to repay $50 mln of term loan, plus accrued interest and associated fees, and the remainder for development and regulatory activities relating to bezuclastinib and other product candidates, anticipated commercialization of bezuclastinib, among other purposes

** Jefferies and JP Morgan are joint bookrunners for CBs offering. JP Morgan, Jefferies, Leerink and Guggenheim are leading the equity deal

** Waltham, Massachusetts-based COGT has ~142.4 mln shares outstanding for about $4.6 bln market cap, including the gain on Mon

** COGT shares edging down 0.3% to $32.35 after the bell

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))